DIAGNOSTIC AND PROGNOSTIC VALUE OF β2-MICROGLOBULIN IN CHRONIC KIDNEY DISEASE
DOI:
https://doi.org/10.47390/3030-3133V3I2Y2025N02Keywords:
β₂-microglobulin, chronic kidney disease, early markers, uremic toxins, CKD progressionAbstract
In this study, the concentration of β₂-microglobulin in blood serum was studied in patients with stage I–III chronic kidney disease (CKD). 68 patients and 20 practically healthy individuals, comparable in gender and age, were examined. The level of β₂-microglobulin was determined by the enzyme immunoassay. The results demonstrated a significant increase in the concentration of β₂-microglobulin already in the early stages of CKD, followed by an increase as the glomerular filtration rate decreases. An increase in β₂-microglobulin may reflect both tubular dysfunction and increasing uremic toxicosis. These data emphasize the prognostic significance of β₂-microglobulin as one of the early markers of CKD progression.
References
1. Авганбекова Г.М., Турсунова Л.Д., Жаббаров О.О. ЗАВИСИМОСТЬ АНГИОГРАФИЧЕСКИХ ХАРАКТЕРИСТИК ПОРАЖЕНИЙ КОРОНАРНЫХ АРТЕРИЙ ОТ ФАКТОРОВ РИСКА СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ У БОЛЬНЫХ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ //SCHOLAR. – 2025. – Т. 3. – №. 1. – С. 108-115.
2. Жаббаров О. О., Турсунова Л. Д., Хужаниязова Н. К. ВНУТРИПОЧЕЧНАЯ ГЕМОДИНАМИКА ПРИ ДИАБЕТИЧЕСКОЙ НЕФРОПАТИИ //Академические исследования в современной науке. – 2024. – Т. 3. – №. 44. – С. 114-115.
3. Мирзаева, Ш. X., et al. "Сурункали буйрак касаллиги бўлган беморларда кардиоренал синдромни даволаш." (2022).
4. Bataille R., Klein B. The role of beta 2-microglobulin in multiple myeloma. Blood. 1986;68(3):583–586.
5. Bernard A.M. Clinical significance of urinary proteins in nephrology. Clin Nephrol. 1989;32(1):42–46.
6. Cohen G., Haag-Weber M., Hörl W.H. Immune dysfunction in uremia. Kidney Int Suppl. 1997;62:S79–S82.
7. Cummings J, et al. (2018). "Use of β2-microglobulin in the evaluation of chronic kidney disease." Nephrology Review, 16(2), 22-28.
8. Eckardt K.U., Coresh J., Devuyst O., et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382(9887):158–169.
9. Erlandsen E.J., Randers E., Kristensen J.H. Reference intervals for serum beta2-microglobulin and cystatin C in adults. Clin Chem Lab Med. 1998;36(11):905–909
10. Filler G., Priem F., Lepage N., et al. β2-Microglobulin in renal disease. Clin Biochem. 2001;34(4):237–247.
11. Garcia-Garcia, G., et al. (2017). "Prognostic value of β2-microglobulin for end-stage renal disease." Nephrology, 22(8), 675-683.
12. Han WK, et al. (2002). "Urinary biomarkers for early detection of acute kidney injury." Kidney International, 62(4), 1205-1212.
13. Hsu C.Y., Chertow G.M. β2-Microglobulin predicts mortality in chronic kidney disease. Clin Nephrol. 2006;66(4):235–241.
14. Jabbarov O. O. Disorders Function of the Heart and Kidney in Diabetes Mellitus. – 2023.
15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–150.
16. Kao, C.-Y., et al. (2019). "Correlation of β2-microglobulin and cystatin C in kidney function assessment." Kidney International, 56(5), 2085-2092.
17. Lee S, et al. (2019). "β2-microglobulin as a prognostic marker in chronic kidney disease." Clinical Journal of the American Society of Nephrology, 14(9), 1301-1308.
18. Levey AS, et al. (2007). "Chronic kidney disease: basic principles and clinical practice." The Lancet, 370(9582), 939-953.
19. Levin A., Stevens P.E. Summary of KDIGO 2012 CKD Guideline: A clinical practice approach. Kidney Int. 2014;85(5):879–883.
20. Liu Y, et al. (2020). "β2-microglobulin in chronic kidney disease: Its role in diagnosis and prognosis." Clinical Nephrology, 93(3), 137-144.
21. Maduell F, et al. (2018). "β2-microglobulin as a diagnostic marker for chronic kidney disease." Nephrology Dialysis Transplantation, 33(4), 701-707.
22. Matsushita K., van der Velde M., Astor B.C., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality. Lancet. 2010;375(9731):2073–2081.
23. O'Neill WC, et al. (2015). "β2-microglobulin: A key marker for kidney disease in diabetes." Diabetes Care, 38(6), 1105-1112.
24. Schardijn G.H., Statius van Eps L.W. Beta2-microglobulin: its significance in the evaluation of renal function. Kidney Int. 1987;32(5):635–641.
25. Shinkai S., Chaves P.H., Fujiwara Y., et al. β2-Microglobulin and mortality among older adults in the community. Clin Exp Nephrol. 2006;10(4):282–288.
26. Thomas R, et al. (2018). "Limitations of creatinine in the diagnosis of kidney disease." Nephrology and Dialysis Transplantation, 33(4), 707-715.
27. Tursunova L. D., Jabbarov O. O. APPLICATION OF SAKABUTRIL/VALSARTAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH TYPE 2 DIABETES MELLITUS //Art of Medicine. International Medical Scientific Journal. – 2021. – Т. 1. – №. 1.
28. Tursunova L., Jabbarov O. O. THE ROLE OF RENAL VASCULAR DOPPLEROGRAPHY IN THE DIAGNOSIS OF CHRONIC KIDNEY DISEASE //Медицинский журнал молодых ученых. – 2024. – №. 12 (12). – С. 52-57.
29. Wong J.Y., Lee S., Choi M.J. Serum and urinary beta-2 microglobulin levels in chronic kidney disease. Korean J Intern Med. 2015;30(3):476–484.
30. Erlandsen E.J., Randers E., Kristensen J.H. Reference intervals for serum beta2-microglobulin and cystatin C in adults. Clin Chem Lab Med. 1998;36(11):905–909
